NEULANDLABPharmaceuticals
Neuland Laboratories Ltd — Cash Flow Statement
₹12027.00
-1.94%
Neuland Laboratories Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 110.92 Cr | 117.51 Cr | 171.08 Cr | -37.30 Cr | — |
| Repayment Of Debt | -39.44 Cr | -48.26 Cr | -116.68 Cr | -22.26 Cr | — |
| Issuance Of Debt | 94.78 Cr | 8.82 Cr | 3.10 Cr | 45.13 Cr | — |
| Capital Expenditure | -206.46 Cr | -143.67 Cr | -66.13 Cr | -97.69 Cr | — |
| End Cash Position | 131.93 Cr | 87.58 Cr | 45.42 Cr | 5.09 Cr | — |
| Beginning Cash Position | 87.58 Cr | 45.42 Cr | 5.09 Cr | 2.44 Cr | — |
| Effect Of Exchange Rate Changes | 0.17 Cr | -0.05 Cr | 0.41 Cr | 0.06 Cr | — |
| Changes In Cash | 44.19 Cr | 42.21 Cr | 39.92 Cr | 2.59 Cr | — |
| Financing Cash Flow | 24.96 Cr | -69.28 Cr | -135.80 Cr | 37.72 Cr | — |
| Interest Paid Cff | -8.38 Cr | -14.05 Cr | -13.15 Cr | -13.56 Cr | — |
| Cash Dividends Paid | -17.96 Cr | -12.83 Cr | -6.41 Cr | -3.85 Cr | — |
| Common Stock Dividend Paid | -17.96 Cr | -12.83 Cr | -6.41 Cr | -3.85 Cr | — |
| Net Issuance Payments Of Debt | 55.34 Cr | -39.44 Cr | -113.58 Cr | 57.66 Cr | — |
| Net Short Term Debt Issuance | 0.00 | -11.16 Cr | -81.06 Cr | 34.80 Cr | — |
| Short Term Debt Payments | 0.00 | -11.16 Cr | -81.06 Cr | — | -111.44 Cr |
| Net Long Term Debt Issuance | 55.34 Cr | -28.28 Cr | -32.52 Cr | 22.87 Cr | — |
| Long Term Debt Payments | -39.44 Cr | -37.10 Cr | -35.62 Cr | -22.26 Cr | — |
| Long Term Debt Issuance | 94.78 Cr | 8.82 Cr | 3.10 Cr | 45.13 Cr | — |
| Investing Cash Flow | -298.16 Cr | -149.69 Cr | -61.50 Cr | -95.52 Cr | — |
| Interest Received Cfi | 9.29 Cr | 7.89 Cr | 1.54 Cr | 1.09 Cr | — |
| Net Investment Purchase And Sale | -197.58 Cr | -15.17 Cr | 1.60 Cr | 1.66 Cr | — |
| Sale Of Investment | 0.03 Cr | 0.34 Cr | 1.60 Cr | 1.66 Cr | — |
| Purchase Of Investment | -197.61 Cr | -15.51 Cr | — | — | — |
| Net Investment Properties Purchase And Sale | 95.43 Cr | 0.00 | 0.00 | -1.01 Cr | — |
| Sale Of Investment Properties | 95.43 Cr | 0.00 | — | — | — |
| Net PPE Purchase And Sale | -205.30 Cr | -142.41 Cr | -64.64 Cr | -97.25 Cr | — |
| Sale Of PPE | 1.16 Cr | 1.26 Cr | 1.49 Cr | 0.44 Cr | — |
| Purchase Of PPE | -206.46 Cr | -143.67 Cr | -66.13 Cr | -97.69 Cr | — |
| Operating Cash Flow | 317.38 Cr | 261.18 Cr | 237.21 Cr | 60.39 Cr | — |
| Taxes Refund Paid | -74.73 Cr | -111.60 Cr | -43.63 Cr | -20.49 Cr | — |
| Change In Working Capital | 57.78 Cr | -90.73 Cr | -12.83 Cr | -67.58 Cr | — |
| Change In Other Current Liabilities | -29.06 Cr | -10.07 Cr | 87.96 Cr | -10.12 Cr | — |
| Change In Other Current Assets | 9.01 Cr | -19.15 Cr | -4.93 Cr | 16.95 Cr | — |
| Change In Payable | 58.76 Cr | 20.33 Cr | 54.36 Cr | -39.72 Cr | — |
| Change In Inventory | -35.34 Cr | -71.19 Cr | -14.02 Cr | -17.60 Cr | — |
| Change In Receivables | 54.91 Cr | -8.66 Cr | -134.33 Cr | -17.10 Cr | — |
| Other Non Cash Items | -2.29 Cr | 5.77 Cr | 11.51 Cr | 12.50 Cr | — |
| Provisionand Write Offof Assets | 1.70 Cr | -0.25 Cr | 4.67 Cr | 0.57 Cr | — |
| Depreciation And Amortization | 65.55 Cr | 59.70 Cr | 52.78 Cr | 49.04 Cr | — |
| Amortization Cash Flow | 1.32 Cr | 1.06 Cr | 1.26 Cr | 1.48 Cr | — |
| Depreciation | 64.22 Cr | 58.64 Cr | 51.52 Cr | 47.56 Cr | — |
| Gain Loss On Investment Securities | -84.09 Cr | — | — | -0.59 Cr | -13.09 Cr |
| Net Foreign Currency Exchange Gain Loss | -0.19 Cr | -3.55 Cr | 8.10 Cr | 2.90 Cr | — |
| Gain Loss On Sale Of PPE | 7.31 Cr | 0.40 Cr | 0.87 Cr | 1.81 Cr | — |
| Net Income From Continuing Operations | 346.33 Cr | 401.44 Cr | 215.75 Cr | 82.16 Cr | — |
| Purchase Of Investment Properties | — | — | 0.00 | -1.01 Cr | 0.00 |
| Pension And Employee Benefit Expense | — | — | -1.87 Cr | 0.08 Cr | -5.11 Cr |
| Short Term Debt Issuance | — | — | — | 34.80 Cr | — |
| Net Other Investing Changes | — | — | — | — | 18.81 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Neuland Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.